By Finance Pulse in KeyInfo —

Citius Pharmaceuticals Upgraded to Buy with $9 Target

Citius Pharmaceuticals (CTXR) gets a Buy upgrade from D. Boral Capital with a $9 price target, driven by the anticipated commercialization of Lymphir.

A sleek, modern depiction of a pharmaceutical lab with a focus on innovation and progress, featuring
Citius Pharmaceuticals Upgraded to Buy with $9 Target

Citius Pharmaceuticals (CTXR) upgraded to Buy from Hold by D. Boral Capital with a $9 price target due to forthcoming commercialization of Lymphir.

Source